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Abstract 
Background: Correct identification of the amyloidosis‑causing protein is crucial for clinical management. Recently 
the Mayo Clinic reported laser‑capture microdissection (LCM) with liquid chromatography‑coupled tandem mass 
spectrometry (MS/MS) as a new diagnostic tool for amyloid diagnosis. Here, we report an independent implemen‑
tation of this proteomic diagnostics method at the Princess Alexandra Hospital Amyloidosis Centre in Brisbane, 
Australia.
Results: From 2010 to 2014, 138 biopsies received from 35 different organ sites were analysed by LCM‑MS/MS using 
Congo Red staining to visualise amyloid deposits. There was insufficient tissue in the block for LCM for 7 cases. An 
amyloid forming protein was ultimately identified in 121 out of 131 attempted cases (94 %). Of the 121 successful 
cases, the Mayo Clinic amyloid proteomic signature (at least two of Serum Amyloid P, ApoE and ApoA4) was detected 
in 92 (76 %). Low levels of additional amyloid forming proteins were frequently identified with the main amyloid form‑
ing protein, which may reflect co‑deposition of fibrils. Furthermore, vitronectin and clusterin were frequently identi‑
fied in our samples. Adding vitronectin to the amyloid signature increases the number of positive cases, suggesting 
a potential 4th protein for the signature. In terms of clinical impact, amyloid typing by immunohistochemistry was 
attempted in 88 cases, reported as diagnostic in 39, however, 5 were subsequently revealed by proteomic analysis to 
be incorrect. Overall, the referring clinician’s diagnosis of amyloid subtype was altered by proteomic analysis in 24 % of 
cases. While LCM‑MS/MS was highly robust in protein identification, clinical information was still required for subtyp‑
ing, particularly for systemic versus localized amyloidosis.
Conclusions: This study reports the independent implementation and evaluation of a proteomics‑based diagnostic 
for amyloidosis subtyping. Our results support LCM‑MS/MS as a powerful new diagnostic technique for amyloidosis, 
but also identified some challenges and further development opportunities.
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Background
Amyloidosis is a rare but devastating condition caused 
by deposition of misfolded proteins as aggregates in the 
extracellular tissues of the body, leading to impairment of 
organ function [1]. Many, but not a limitless number of 
proteins can cause amyloidosis [2]. The most common are 
immunoglobulin light chain (AL), transthyretin (ATTR), 
serum amyloid A protein (AA) and the alpha chain of 
fibrinogen (AFib). Treatment and prognosis depend on 
identifying the culprit protein [3]. Treatment aimed at 
reducing the amyloidogenic protein involves preventing 
production and aggregation of these misfolded proteins. 
For example, in AL amyloidosis chemotherapy is required 
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to kill the clonal bone marrow plasma cells that produce 
the pathologic immunoglobulin light chain. Such thera-
pies are inappropriate and in fact harmful for other types 
of amyloidosis. Similarly, accurate diagnosis of amy-
loid subtype is critical to guide organ transplantation to 
replace the organ that manufactures the pathogenic pro-
tein in hereditary amyloidosis [4]. Correct identification 
of the causal amyloid protein is thus absolutely crucial for 
clinical management in order to avoid misdiagnosis and 
inappropriate, potentially harmful treatment, to assess 
prognosis, and to offer genetic counselling if relevant.
In clinical diagnostic laboratories the diagnosis of amy-
loidosis is made by histological examination of tissue 
biopsy samples with the presence of amyloidosis dem-
onstrated by the Congo red immunohistochemical stain 
which results in a pale ‘salmon-pink’ staining that shows 
typical birefringence and dichroism effects when exam-
ined under polarised light microscopy [5]. Subtyping of the 
amyloid deposits is made by the use of immunohistochem-
ical (or immunofluorescence) stains for the various poten-
tial amyloid proteins [6]. This is problematic as, outside of 
highly specialised centres, these stains are often unreliable 
giving both false positive and false negative findings [7, 8]. 
Recently, the Mayo Clinic has established the use of laser 
capture microdissection (LCM) followed by tandem mass 
spectrometry (MS) to identify the subtype of amyloid with 
a high degree of confidence from clinical biopsy samples 
[9–11]. In this study we report the implementation and 
evaluation of this novel diagnostic technique at a tertiary 
referral hospital in Brisbane Australia over 5 years.
Methods
Clinical specimens
The study was approved by the Princess Alexandra Hos-
pital Ethics Committee. Diagnostic formalin fixed paraf-
fin embedded tissue biopsy samples from 138 patients 
referred to the Princess Alexandra Hospital Amyloi-
dosis Centre between 2010 and 2014 were used for this 
study. Seven of these had insufficient tissue remaining 
in the block for LCM. Clinicians referring patient biopsy 
samples were required to complete a baseline proforma 
of clinical details of the case and were asked to indicate 
their clinical diagnosis of amyloid subtype.
Specimen microdissection and processing
Ten micron sections were cut from formalin fixed paraf-
fin embedded tissue onto Arcturus PEN membrane glass 
slides. Tissue sections were deparaffinised and stained 
with Congo red. The stained sections were rinsed and 
thoroughly air-dried. Congo red positive areas were dis-
sected using an Arcturus LCM system. Amyloid regions 
were processed according to the Stratagene FFPE pro-
tein extraction protocol. Briefly, LCM samples were 
incubated with FFPE protein extraction solution at 90 °C 
for 10 min, followed by 60 °C for 120 min and alkylation 
with 167 mM of iodoacetamide for 30 min. Samples were 
diluted 10 times with 50  mM ammonium bicarbonate 
and 10 % acetonitrile for overnight digestion with 0.1 μg/
μl trypsin at 37 °C. Trypsin inactivation was achieved by 
acidifying samples with 0.1 % formic acid. Buffer volumes 
were adjusted on the basis of the LCM size, however, all 
concentrations remained constant.
Tandem mass spectrometry and classification
Extracted peptides (8  μl) were analysed with high per-
formance liquid chromatography (HPLC) coupled Chip-
cube QTOF mass spectrometer 6520 or 6530 (Agilent 
Technologies). Solvent A composition was 0.1  % formic 
acid, solvent B was 0.1 % formic acid, 90 % acetonitrile. 
Samples were desalted on the enrichment column of 
G4240-62010 C18 HPLC chip for 12 s prior to a 20 min 
gradient from 5 to 50 % B. HPLC loading pump was set 
to 2.5  % B, flow rate of 3  μl/min while analytical pump 
was set to 5 % B and flow rate of 0.3 μl/min. Mass spec-
trometer was programmed to acquire 8 MS and 4 MS/
MS spectra/sec with dynamic exclusion after 2 MS/MS 
and released after 0.2 min.
Mass spectrometry data was analysed using Spectrum 
Mill search engine against NCBInr human database with 
carbamidomethylation cysteine as fixed modification, 
and oxidized methionine, pyroglutamic acid N-term, and 
deamidated asparagine as variable modifications. Protein 
identification cut-offs were protein score >11, peptide 
score >10 and % scored peak intensity >60. For each case 
the protein score for known amyloidogeneic proteins and 
known amyloid-associated proteins was calculated. Amy-
loid subtype was ascribed to the amyloidogeneic protein 
with the highest score.
Distinction between localized and systemic light chain 
amyloidosis was based on clinical information. Localized 
amyloidosis had amyloid deposits in only one site in the 
absence of a circulating clonal light chain. Systemic AL 
amyloidosis had an identified clonal plasma cell or lym-
phoproliferative population distant from the amyloid site.
Statistical analysis
All statistical analyses were performed using the R sta-
tistical software (https://www.R-project.org/). Shap-
iro–Wilk tests confirmed the non normality of the data 
therefore Spearman’s rank correlation were used to assess 
correlation between parameters and non parametric 
Mann–Whitney U test were used to assess median dif-
ferences in those parameters between negative and posi-
tive Mayo signature. Fisher’s exact tests were performed 
to evaluate the significance of the relative proportion of 
samples found within proteins of interest.
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Results
LCM‑MS/MS identification of amyloid forming proteins
LCM-MS/MS was attempted on 131 clinical biopsy sam-
ples referred to the Princess Alexandra Hospital Amy-
loidosis Centre between April 2010 and December 2014 
(Fig. 1). Seven additional cases were not analysed due to 
lack of tissue in the block. The biopsy samples came from 
35 different organ sites, with the most common organs 
of origin being heart (n  =  24), kidney (n  =  17), colon 
(n = 8) and small bowel (n = 7). Of the 131 cases an amy-
loid forming protein was identified in 106 cases in the 
first run. Seven cases where no amyloid protein was iden-
tified were due to very scant amyloid deposits in the dis-
sected tissue and further LCM was not attempted. Repeat 
LCM was performed for 18 cases of which 15 had amy-
loid forming proteins identified. Ultimately, an amyloid 
forming protein was identified in 121 of 131 cases, and 
subtyped based on the amyloid forming protein of high-
est score (Table 1; Additional file 1: Table S1). 
A lower level of additional amyloid forming protein(s) 
was also identified in a number of cases. Notably, second-
ary amyloid forming proteins were identified in 23 out of 
26 localized AL cases (88.46 %). In comparison, second-
ary amyloid forming proteins were identified in 18 out of 
46 systemic AL cases (40 %). The proportion of cases with 
secondary amyloid forming proteins was determined to 
be significantly different between localised and systemic 
AL diagnoses (p value = 5.068e−05, Fisher’s exact test).
Various other proteins were also identified by LCM-
MS/MS of amyloid extracts. Of particular interest is the 
presence of proteins typically known to be co-located in 
amyloid deposits which helps confirm that the micro-
dissected tissue is amyloid. Typical amyloid-associated 
proteins were identified in the following number of 
cases: vitronectin (n = 104), apolipoprotein A4 (ApoA4, 
n =  90), apolipoprotein E (ApoE, n =  94), serum amy-
loid P component (SAP, n = 83), and clusterin (n = 45). 
ApoA4, ApoE and SAP were previously suggested by 
the Mayo Clinic as a proteomics signature for amyloid, 
with any two out of the three proteins being sufficient 
to confirm amyloid [12]. Of the 121 successfully diag-
nosed cases, 92 cases (76 %) were positive for the Mayo 
amyloid signature, with distribution shown in Table  2. 
Mann–Whitney U test was used to determine if presence 
of a Mayo amyloid signature (e.g. positive or negative) 
was associated with a more confident amyloid diagno-
sis, as indicated by higher Amyloid score and Amyloid 
% coverage. The p values obtained (p =  1.838e−05 and 
0.0006725, for Amyloid score and Amyloid % cover-
age respectively) indicate that the samples with a posi-
tive Mayo signature provided more confident amyloid 
diagnoses.
In addition to ApoE, SAP and ApoA4, our dataset 
showed frequent identification of vitronectin and clusterin 
in amyloid deposit. Therefore, we investigated the value of 
adding either protein to the Mayo amyloid signature. Clus-
terin was detected in 42 out of 92 cases positive for the 
Mayo amyloid signature, but only 3 out of 29 cases nega-
tive for the Mayo amyloid signature. It was deemed of lim-
ited additional utility. On the other hand, vitronectin was 
detected in 88 out of 92 samples which were positive for 
the Mayo amyloid signature, and 16 out of 29 samples neg-
ative for Mayo amyloid signature. A fisher exact test was 
performed to evaluate whether the relative proportion of 
samples with a presence of vitronectin was independent of 
the number of samples that were found to have a positive 
or negative Mayo signature. A significant association was 
found between the number of samples with the presence of 
vitronectin and the Mayo signature (p value = 9.037e−07, 
Fisher’s exact test). When we add vitronectin into the mix 
and evaluated how many positive diagnoses are identified 
if two of four proteins (i.e. ApoE, ApoA4, SAP and Vitron-
ectin) are identified the total number of positive diagnoses 
increases from a Mayo positive signature in 92 cases to a 
positive amyloid signature in 104 cases.
Impact of LCM‑MS/MS on immunohistochemistical 
and clinical diagnosis of amyloid subtype
Amyloid typing by immunohistochemistry (IHC) had 
been attempted in 88 cases, with 49 reported as non-
diagnostic or uninterpretable, and 39 as diagnostic Fig. 1 Flowchart for samples analysed
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(Additional file  1: Table  1). Five of the latter were sub-
sequently revealed by proteomic analysis to be incor-
rect. Three of the cases with a LCM-MS/MS diagnosis 
of ATTR were elderly men with isolated cardiac amyloi-
dosis, no proteinuria and no paraprotein or clonal light 
chain. These three were misdiagnosed on IHC as AL 
(n = 2) and AA (n = 1). One case with a LCM-MS/MS 
diagnosis of AL was diagnosed on IHC as AA amyloido-
sis. This case had biopsy proven renal involvement, car-
diac involvement, peripheral neuropathy and IgA lambda 
paraprotein. The final case was diagnosed by IHC as AA 
but by LCM-MS/MS was diagnosed as AL amyloidosis. 
This case presented with hepatic, renal, cardiac and gas-
trointestinal organ involvement and had an IgG lambda 
paraprotein.
Overall, the referring clinician’s diagnosis of amyloid 
subtype was altered by proteomic analysis in 24  % of 
cases. Most commonly (n  =  15) the referring clinician 
indicated they were uncertain as to the amyloid subtype, 
but in 11 cases the clinical diagnosis was AL amyloidosis 
Table 1 Major amyloid fibril type identified by LCM-MS/MS
Not shown in the table: 1 case of TGFb, 2 cases of semenogelin, 2 cases of AFib, 2 cases of ALect
Amyloidosis 
subtype
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 Transthyretin 1 3 3 25 6
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 ApoE 21 12 2 16 7 19 6 5
 SAP 16 8 13 6 24 6 4
 ApoA4 23 10 1 16 8 22 6 2
 Amyloid 
signature
63 % 77 % 0 % 100 % 78 % 92 % 100 % 57 %
Table 2 Number of cases identified with proteins from the 
Mayo amyloid signature
ApoE SAP ApoA4 2 out of 3
Negative 27 38 31 29
Positive 94 83 90 92
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but LCM-LC-MS/MS demonstrated the actual subtype 
was ATTR (n = 7), AA (n = 2) and AH (n = 2).
Discussion
Here we report our results with LCM-MS/MS for amyloi-
dosis subtyping in a referral centre with a relatively small 
case load. Since establishing the procedures within the 
proteomics facility of a research institution (The Univer-
sity of Queensland Diamantina Institute) associated with 
the hospital in 2010, we have successfully analysed sam-
ples in batches. Our instrumentation and analysis soft-
ware was different to that reported by the Mayo Clinic 
[9–11, 13, 14]. The overall success rate for LCM-MS/MS 
amyloid identification was 121 out of 138 referred cases 
(88 %), or 121 out of 131 attempted cases (92 %). In con-
trast, our IHC success rate for a subset of the sample was 
45 % (39 out of 87) and 5 of these were incorrect. These 
results highlight the problem with immunohistochemis-
try for subtyping outside of centres of expertise, but also 
demonstrate the robustness of LCM-MS/MS method.
While the success rate for LCM-MS/MS amyloid iden-
tification was high, interpretation is not always straight-
forward and we note several caveats with this technique. 
Firstly, more than one amyloid forming proteins are iden-
tified in many samples. In these cases, we classified by the 
most abundant protein as per Vrana et al. [9]. However, 
in some cases the top two proteins were very similar in 
total intensity. In rare occasions SAA protein has been 
noted as a contaminant in samples analysed after SAA 
amyloid samples. In general amyloid proteins are highly 
hydrophobic proteins which require intensive condition-
ing procedures to elute off reverse phase columns. To 
prevent leaching of contaminants to subsequent analy-
sis, larger LCM samples and samples with SAA protein 
should be diluted, or queued at the end of a batch. Sec-
ondly, in cases of AL amyloidosis, clonality of identified 
immunoglobulins is strengthened by demonstrating the 
light chain or heavy chain variable region rather than the 
constant region, which is not always the case. A new bio-
informatic workflow was recently reported to detect light 
chain variable peptides and may be a useful tool for deter-
mining clonality [15]. Furthermore, clinical information 
is still required for subtyping. For example, systemic ver-
sus localized AL amyloidosis is classified by clinical infor-
mation. Hence, a system to integrate clinical and MS/MS 
data is required. Finally, repeat LCM is required for some 
samples, adding time and cost to the diagnosis. Triaging 
of small LCM samples could be implemented to reduce 
time and resource wastage. Alternatively, imaging mass 
spectrometry technique has recently been reported for 
localized detection of amyloid peptides in situ, and could 
be further evaluated [16].
There are several limitations in the current study, which 
should be addressed in the future. Firstly, not all of the 
cases were fully worked up with all immunohistochemi-
cal staining and so a “gold standard” diagnosis could not 
always be assigned. In some cases the initial MS failed for 
various reasons and a second LCM and MS analysis was 
required to attain a diagnosis. Secondly, while our data 
suggest vitronectin to be a potential new amyloid signa-
ture protein, LCM-MS/MS demonstrating the absence 
of vitronectin in adjacent normal tissue and in tissues 
involved by non-amyloid pathology would be required. 
Finally, there were few hereditary amyloid cases in our 
cohort, and our methodology is not optimized for muta-
tion detection.
Conclusions
In conclusion, our study supports LCM-MS/MS as a 
robust diagnostic platform for identification of fibril 
composition of amyloid deposits in clinical biopsy sam-
ples. Further optimization and standardization of the 
methodology will be required to add LCM-MS/MS as 
an additional arsenal in amyloid subtyping. Future work 
should standardize the sample preparation methodology, 
establish a specialized database to account for immu-
noglobulins and amyloidogenic mutations and finally 
develop and standardize bioinformatic diagnosis meth-
odology incorporating clinical and LC-MS/MS data.
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